Background: The effect of ART on endothelial cell function is incompletely characterized.
Introduction
Vascular homeostasis is generally the result of the equilibrium between opposing mechanisms of endothelial damage and repair or remodelling. Endothelial dysfunction is characterized mainly by a decrease in the bioavailability of vasodilators, particularly nitric oxide, and/or an increase in the number of relaxing factors derived from the vascular wall. The resulting imbalance leads to impaired endothelium-dependent vasodilatation. [1] [2] [3] In addition, injury to blood vessels is associated with increased levels of platelets and of components released from the vasculature as circulating endothelial cells (CECs). Restoration of vascular integrity requires the active contribution of distinct cell populations, such as circulating endothelial progenitor cells (EPCs) and accessory or supportive circulating angiogenic cells (CACs). 4 These cells are commonly mobilized from bone marrow to the bloodstream so that they can enter target tissues. [4] [5] [6] [7] [8] [9] In fact, common cardiovascular risk factors, such as hypertension, diabetes, smoking and hyperlipidaemia, have been associated with low peripheral levels of EPCs. [7] [8] [9] HIV infection is characterized by chronic inflammation and hyperactivation of the immune system, which in turn trigger other chronic inflammatory processes, such as atherosclerosis. The proinflammatory state and pro-thrombotic phenomena induced in the vascular endothelium explain the increased risk of cardiovascular disease in HIV-infected individuals, independently of traditional risk factors. [10] [11] [12] Remarkably, untreated HIV replication has been associated with high levels of CECs and endothelial V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. microparticles released from injured endothelia, both of which have been considered surrogate markers of vascular damage. [13] [14] [15] [16] [17] The use of the ritonavir-boosted PIs lopinavir and indinavir has been associated with an increase in cardiovascular risk that was initially attributed to their negative impact on the lipid profile. [18] [19] [20] [21] However, a direct effect of these agents on the endothelial wall has recently been suggested. 18, 19, [21] [22] [23] Many clinical trials and in vitro studies have reported endothelial dysfunction associated not only with the virus itself, but also with some antiretroviral agents through decreased expression of endothelial nitric oxide synthase and increasing cellular oxidative stress. 18, 21, 22 In addition, several trials show that some antiretroviral drugs exacerbate injury by inducing vascular smooth muscle cell proliferation and neointimal hyperplasia as a consequence of endothelial wall dysfunction. 11, [14] [15] [16] 19, [21] [22] [23] While both conditions described above may be linked, the exact mechanisms through which antiretrovirals, particularly PIs, promote endothelial injury are unknown. 18, [21] [22] [23] Indeed, it is unknown whether the negative effect on the endothelial wall attributed to these drugs is antiretroviral class-related toxicity or whether the latest generation PIs have no effect on endothelial dysfunction. 24, 25 We performed the present study to assess the impact of one of the most commonly used PIs, darunavir (ritonavir-boosted) and the NNRTI rilpivirine on endothelial homeostasis by comparing levels of CECs, EPCs and CACs between HIV-infected individuals and healthy volunteers.
Methods

Study population and classification
We included 24 antiretroviral-naive HIV-infected patients consecutively attending in the outpatient clinic of our hospital between January 2012 and April 2012. Candidates had to have a plasma viral load between 20000 and 80000 copies/mL before starting therapy and to have started a regimen containing darunavir/ritonavir plus tenofovir/emtricitabine or rilpivirine plus tenofovir/emtricitabine. Patients with a history of acute illness, cardiovascular events in the last 6 months or cardiovascular risk factors (hypertension, dyslipidaemia, smoking habit, lack of exercise or obesity) were excluded from the study.
Investigators of the study did not assign the ART. The study was proposed to all consecutive HIV-infected patients from our unit whose physician decided to start ART with darunavir/ritonavir plus Truvada V R or rilpivirine plus Truvada V R , and who fulfilled the remaining study selection criteria. Participants were classified according to their antiretroviral regimen as follows: (i) darunavir group, i.e. patients started ritonavir-boosted darunavir plus tenofovir/emtricitabine (n " 12), or (ii) rilpivirine group, i.e. patients started rilpivirine plus tenofovir/emtricitabine (n " 12).
An additional 24 non-HIV-infected volunteers matched by gender and age (+3 years) with the HIV-infected participants and with no history of acute illness, cardiovascular events or cardiovascular risk factors who agreed to participate were also recruited by hospital staff and through a local advertisement (the control group).
Ethics
Written informed consent was obtained from all participants prior to study entry. Trial protocols were reviewed and approved by the appropriate institutional ethics committees and health authorities (EPA-13-001). The study was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.
Study design and objectives
We performed a 24 week prospective, case-control and comparative pilot study of antiretroviral-naive HIV-infected individuals who started a darunavir/ritonavir-or rilpivirine-based regimen and age-and sex-matched non-HIV-infected volunteers. The objective was to compare endothelial dysfunction between the three groups by measuring changes in peripheral levels of CECs, EPCs and CACs, as well as changes in immune-activation markers at week 24. In addition, changes in these endothelial mature and precursor cells were correlated with virological, immunological and clinical parameters.
Assessments and follow-up
Blood samples were obtained from all participants after at least 10 h of fasting, before starting ART and 4, 12 and 24 weeks later in the darunavir and rilpivirine groups and at baseline and 24 weeks in non-HIV-infected subjects. Fresh blood samples were labelled with the following antibody combinations (all antibodies were from Becton Dickinson, unless otherwise indicated): (i) V450-CD45, FITC-CD34, PerCP-Cy5.5-CD31, PE-Cy7-CXCR4 (eBioscience) and PE-CD133 (Milteny) for evaluation of circulating endothelial cells, and (ii) APC-Cy7-CD3, APC-CD4, V500-CD8, PE-Cy7-CD45RO, FITC-HLA-DR, PerCP-Cy5.5-CD38 and PE-PD-1 for evaluation of changes in immune activation. Data were acquired in an LSR-II flow cytometer (Becton Dickinson). The analysis was carried out using FlowJo software (9.2.3v). According to the gating strategy described in Figure S1 (available as Supplementary data at JAC Online), at each time point, we determined the frequency and absolute counts of the following cell populations:
! cells). Activation and exhaustion markers were also analysed in the CD4 and CD8 T cell populations (CD38 ! HLADR ! and PD-1 ! cells, respectively). The other laboratory data recorded at the various time points included plasma HIV-1 RNA (determined using the AMPLICOR HIV-1 MONITOR Test, v 1.5; Roche Diagnostic, Basel, Switzerland), CD4 and CD8 lymphocyte counts, serology of hepatitis C and B virus, and routine haematology and biochemistry findings.
Sociodemographic features (age, gender, race) and HIV-related data (time since diagnosis of HIV infection, risk transmission group, nadir CD4 T cell count) were recorded from the patients' records.
Statistical analysis
We prepared a statistical summary for the main variables, as well as a pictorial and tabular description. The differences between groups and the longitudinal changes were assessed using the Wilcoxon, Mann-Whitney, v 2 and Fisher exact tests, as appropriate.
We used a multiple linear regression model to study the relationship between the outcomes of interest (plasma levels of CECs, EPCs, CACs and immune-activation markers) and the covariates.
All analyses were performed using SPSS, version 16 (SPSS Inc., Chicago, IL, USA).
Results
The study population comprised 48 participants: 24 HIV-infected individuals and 24 non-HIV-infected controls. The main demographic and clinical characteristics of the study population are shown in Table 1 . Most participants were men and the median (IQR) age was 33.2 (22-48) years in the HIV group and 34.6 (22-49) years in the control group. Virological, immunological and biochemical parameters, including the median CD4 T cell count and viral load, were well balanced at baseline between the HIV-infected groups.
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Immunological and virological responses to combination ART
All participants in the HIV-infected groups achieved suppressed viraemia (viral load ,50 copies/mL) after 24 weeks of treatment. The CD4 T cell count increased significantly from baseline to 24 weeks in both groups (P " 0.003 in the rilpivirine group and P " 0.015 in the darunavir group), with no differences between them at week 24 (P " 0.406).
Levels of activation and exhaustion markers in CD8 T cell populations (measured as the frequency of CD38 ! HLADR ! and PD-1 ! CD8 T cells, respectively) were significantly higher at baseline in both HIV-infected groups than in the control group (P , 0.001 for both). No differences between the HIV-infected groups were observed at baseline for activation or exhaustion markers (P " 0.171 and P " 0.510, respectively) ( Figure 1 ). Activation marker levels decreased significantly after initiation of both antiretroviral regimens (P " 0.004 in the rilpivirine group and P " 0.009 in the darunavir group), although the differences remained between HIV-infected patients and the controls at week 24, with higher levels of immune-activation or exhaustion markers (P , 0.001 and P , 0.001, respectively) ( Figure 1 ). However, no statistical differences were seen between the darunavir and rilpivirine groups at week 24 for immune activation (P " 0.983). After 24 weeks of treatment, the percentages of PD-1 ! CD8 T cells were higher only in the rilpivirine group than in the control group (P " 0.001).
Vascular injury and levels of CECs, EPCs and CACs
-cells) were more frequent among the HIV-infected groups than the control group at baseline (P " 0.033), whereas no statistical differences were seen among the darunavir and rilpivirine groups (P " 0.378) (Figure 2 , left panel). Although the rilpivirine group showed a decrease in levels of CECs after 24 weeks of treatment (P " 0.002), these levels remained statistically higher when we compared the rilpivirine group with the control group (P " 0.015) and with the darunavir group (P " 0.020) at week 24.
Interestingly, no significant differences were detected between the darunavir group and the control group at week 24 (P " 0.988) (Figure 2, left panel) . Levels of CECs remained stable in the control group.
The analysis of both EPC and CAC levels at baseline showed that they were lower in both of the HIV groups than in the control group (P " 0.044 and P " 0.005, respectively). Remarkably, no significant differences were observed between the darunavir group and the control group for EPCs or CACs at week 24 (P " 0.705 and P " 0.077, respectively). In contrast, no recovery of EPC and CAC populations was seen in the rilpivirine group (EPCs even significantly decreased, P " 0.008) and differences at week 24 with the control group were maintained (P " 0.018 and P " 0.024, respectively) (Figure 2 , middle and right panels).
Regression analysis
Multiple regression analysis of the whole study population revealed no associations between changes in endothelial cells and other clinical and epidemiological variables included in the unadjusted analysis.
However, when only HIV-infected individuals were included in the analysis, we observed associations between high baseline HIV-RNA viral load and low baseline levels of EPCs (b coefficient with PIs and endothelial cells JAC 95% CI #1.01 to 37.68) and age with high baseline levels of CECs (b coefficient with 95% CI #1.28 to #0.18). At week 24, the only association with low levels of CACs was observed with rilpivirine (b coefficient with 95% CI 4.39-27.21).
Discussion
Our approach to the endothelium has advanced gradually over the last few decades. Whereas it was initially considered a simple inert barrier between blood vessels and underlying tissues, it is now considered to be a highly specialized layer of cells (endothelial cells) that play crucial roles in homeostasis through the exchange of nutrients, gases and waste products to and from cells. [3] [4] [5] [6] Among the various human adult progenitor cells that have been documented, those in the bone marrow and those circulating in the peripheral blood collectively (and sometimes erroneously), i.e. EPCs, have received much attention for their role in the promotion of vascular growth and repair. 4 These cell populations, which are known as CACs, endothelial colony-forming units-Hill and endothelial colonyforming cells, varied in terms of phenotype, contribution to vascular homeostasis and purity, although they are mostly not genuine vascular precursor cells (i.e. they do not belong to the endothelial cell lineage). 4 Moreover, there is compelling evidence that alterations in the systemic levels of CECs, EPCs and CACs are directly associated with vascular dysfunction and subsequent neovascularization processes in multiple diseases. 3, [5] [6] [7] [8] [9] [10] [14] [15] [16] [17] Nevertheless, the role of EPCs in vascular homeostasis in HIV-infected individuals is unknown, since several factors (viral replication, inflammation, immune activation, senescence and ART) seem to have a direct effect on endothelial homeostasis. [11] [12] [13] [14] [15] [16] 22, 23, 26 Uncontrolled viral replication is the main reason for systemic immune activation and chronic inflammation among HIV-infected individuals. [11] [12] [13] [14] [15] [16] However, despite maintenance of virological suppression with ART, hyperactivity of the immune system and a hypercoagulation state may persist. 11 In fact, this population never reaches the background levels of non-infected subjects. 11, 12, 17, 27 The chronic activation and the proinflammatory state contribute to the high prevalence of morbidities, such as atherothrombosis, neurocognitive disorders, liver steatosis and osteoporosis, which are currently challenging. In fact, increased knowledge of the pathogenesis of these comorbidities is essential if their prevalence and mortality are to be reduced. Echeverr ıa et al.
In the present study, antiretroviral-naive HIV-infected patients had increased levels of circulating activation markers before starting ART. These decreased after 24 weeks of treatment independently of the treatment regimen, but without reaching the levels of non-infected subjects, thus supporting the negative role of HIV infection on immune hyperactivation and the only partial improvement observed despite initiation of ART and viral suppression. [11] [12] [13] Our results support the well-documented direct damage of the virus itself on the endothelial wall. The uncontrolled HIV replication among antiretroviral-naive individuals in our study was associated with high levels of CECs, indicating greater vascular damage than in non-infected subjects, and with low levels of EPCs and CACs, suggesting less effective endothelial repair. Multiple regression analysis confirmed an association between high baseline HIV-RNA and low levels of baseline EPCs, and age with high levels of CECs, both negative factors leading to endothelial damage. [28] [29] [30] After 24 weeks of treatment with darunavir, CEC levels were similar to those of non-HIV-infected subjects, decreasing also in the rilpivirine group, but without reaching the level of the non-HIVinfected subjects. On the other hand, rilpivirine-treated individuals had lower levels of EPCs and CACs than non-infected participants at week 24, indicating poor repair and neovascularization. Importantly, the restoration of EPC and CEC levels observed in darunavir-treated individuals indicates effective mobilization of vascular progenitor cells from bone marrow to the circulatory system, thus suggesting ongoing angiogenic repair mechanisms. Our data suggest a protective effect of darunavir in the repair and recovery of the endothelium.
The differences between CECs and EPCs/CACs in the rilpivirine and darunavir groups cannot be explained by differences in the prevalence of traditional cardiovascular risk factors, because individuals with risk factors were excluded from the study. In addition, no differences between the antiretroviral regimens were observed with respect to antiviral efficacy and reduced immune activation at week 24.
In contrast with our results, several studies have reported an unfavourable effect of PIs on vascular function induced by vascular endothelial cell dysfunction, production of reactive oxygen species, inflammation and senescence. [18] [19] [20] [21] [22] [23] [24] However, most published studies evaluated endothelial function using other techniques (i.e. brachial artery flow-mediated dilation test, change in cardiometabolic parameters and expression of endothelial nitric oxide synthase). 17, [21] [22] [23] [24] [25] Only one previous study directly compared the effect of the latest-generation PIs (atazanavir and darunavir) on vascular integrity through evaluation of endothelial cells. 25 Guaraldi et al. 24 studied the effect of switching triple ART to darunavir/ritonavir monotherapy or darunavir/ritonavir plus two nucleoside analogues (MONARCH Trial) on endothelial function by measuring changes in the flow-mediated dilation test result and determining EPCs and CECs as secondary objectives. They observed that switching from triple therapy to darunavir/ritonavir, with or without nucleoside analogues, did not lead to clinically significant reductions in endothelial function, although a slight increase in the number of endothelial cells was observed. 24 Our data could indicate that ART should be started early to prevent endothelial damage. As antiretroviral drugs have varying impacts on the endothelial wall and, consequently, on long-term cardiovascular risk, we should select the most promising therapies for the prevention of premature cardiovascular disease in HIV-infected patients. Our data show a different impact on the endothelial wall depending on the antiretroviral regimen, although the small sample size and the lack of randomization highlights the need for further randomized investigation in a large cohort of patients with increased follow-up and assessing the new antiretroviral drugs, e.g. integrase inhibitors.
In conclusion, hyperimmune activation and a proinflammatory state were associated with HIV replication and endothelial damage based on levels of CECs. The initiation of ART with darunavir or rilpivirine plus tenofovir/emtricitabine also decreased activation of CD8 cells, although endothelial repair was only observed with darunavir. 
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